Acumen Pharmaceuticals, Inc. (ABOS)
Nasdaq · Healthcare · Biotechnology
$2.13+4.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $154M
- 52-week range
- $1.50 – $3.60
- 52-week change
- +8.51%
- EPS (trailing)
- −$1.64
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$121M
- Diluted EPS
- −$2.00
- Free cash flow
- −$116M
From the company’s annual report on SEC EDGAR.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Headquarters: Newton, United States · 60 employees · acumenpharm.com